Quotient Limited | SARS-CoV-2 Antibody Test
Share this article
Quotient Limited Announces the Completion of the SARS-CoV-2 Antibody Test Development
Vaud-based Quotient Limited announced on 6 April 20202, the completion of its SARS-CoV-2 antibody test development for the fully automated high throughput MosaiQ system in response to the global COVID-19 pandemic.
The antibody test has a broad range of applications such as the ability to identify individuals who would require vaccination once available, and those who could safely return to work. This is especially important for frontline healthcare professionals and others who face significant potential exposure to the virus.